heme iron polypeptide
Ferroheme is formed when iron is inserted into protoporphyrin IX. The active center of hemoglobin and myoglobin consists of iron Ferroheme complex bound through a single, “proximal”, axial histidine (His) to the protein It is an iron containing cofactor that is involved with a wide range of cellular functions including oxygen transport. The antimalarial activity of a number of artemisinin derivatives, both newly synthesized and currently used as drugs, against Plasmodium falciparum in culture shows a correlation with their affinity of binding with Ferroheme. — NCATS
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2007 (NCT00318812)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- ErythropoietinACTIVATOR
EPO activator
Chemistry & pharmacology
SMILES
[Fe++].CC1=C(CCC(O)=O)C2=CC3=NC(=CC4=C(C)C(C=C)=C([N-]4)C=C5N=C(C=C1[N-]2)C(C=C)=C5C)C(C)=C3CCC(O)=O- Mol. weight
- 616.487 g/mol
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIron supplement ↗
- NCATS42VZT0U6YR ↗
- NCATS31VDO12CJY ↗
Also known as
- heme-iron
- heme iron polypeptide
- proferrin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01865175 | Phase 4 | Jan 1, 2016 | Pennsylvania State University |
| NCT01733979 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2012 | Chonbuk National University |
| NCT00318812 | Phase 2/Phase 3 (Phase 3) | May 1, 2007 | University of Ottawa |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chonbuk National University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Pennsylvania State University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Ottawa | Academic/Hospital | 1 | 1 | 1 | 2007 |